Bergen Brunswig
Executive Summary
Chase Manhattan will underwrite $1.5 bil. in a senior, secured credit facility to be finalized in April, Bergen said. The new facility will ease the pressure on Bergen's forward-buying activities. Bergen had announced Jan. 26 that it would not participate in forward buying at normal levels until refinancing of its $600 mil. revolving credit facility due in April was completed (1"The Pink Sheet" Jan. 31, 2000, p. 27)
You may also be interested in...
Bergen Curtails Forward Buying Until April; Stadtlander To Restructure
Bergen Brunswig will curtail its forward buying of inventory until it completes refinancing of its $600 mil. revolving credit facility "in the next six to eight weeks," company CEO Robert Martini said during a conference call Jan. 26.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials